This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greco, W. R. Articles by Rustum, Y. M. Search for Related Content PubMed PubMed Citation Articles by Greco, W. R. Articles by Rustum, Y. M.

Application of a New Approach for the Quantitation of Drug Synergism to the Combination of cis-Diamminedichloroplatinum and 1-ß-D-Arabinofuranosylcytosine¹

Grace Cancer Drug Center [W. R. G., H. S. P., Y. M. R.] and Department of Biomathematics [W. R. G.], Roswell Park Memorial Institute, New York State Department of Health, Buffalo, New York 14263

This report describes the application of a new approach, the universal response surface approach, to the quantitative assessment of drug interaction, i.e., the determination of synergism, antagonism, additivity, potentiation, inhibition, and coalitive action. The specific drug combination and experimental growth system for this introductory application was that of 1-ß-D-arabinofuranosylcytosine (ara-C) and cisplatin with simultaneous drug exposure (1, 3, 6, 12, or 48 h) against L1210 leukemia in vitro. To quantitate the type and degree of drug interaction, a model was fitted using nonlinear regression to the data from each separate experiment, and parameters were estimated (K. C. Syracuse and W. R. Greco, Proc. Biopharm. Sect. Am. Stat. Assoc., 127–132, 1986). The parameters included the mximum cell density over background in absence of drug, the background cell density in presence of infinite drug, the 50% inhibitory concentrations and concentration-effect slopes for each drug, and a synergism-antagonism parameter, . A positive indicates synergism, a negative , antagonism, and a zero , additivity. Maximal synergy was found with a 3-h exposure of ara-C + cisplatin, with = 3.08 ± 0.96 (SE) and 2.44 ± 0.70 in two separate experiments. Four different graphic representations of the raw data and fitted curves provide visual indications of goodness of fit of the estimated dose-response surface to the data and visual indications of the intensity of drug interaction. The universal response surface approach is mathematically consistent with the traditional isobologram approach but is more objective, is more quantitative, and is more easily automated. Although specifically developed for in vitro cancer chemotherapy applications, the universal response surface approach should prove to be useful in the fields of pharmacology, toxicology, epidemiology, and biomedical science in general.

¹ Supported by National Cancer Institute Grants CA18420, CA50456, and CA46732.

² To whom requests for reprints should be addressed.

Received 4/14/89. Revised 2/28/90.

This article has been cited by other articles:

				T. M. Horton, G. Jenkins, D. Pati, L. Zhang, M. E. Dolan, A. Ribes-Zamora, A. A. Bertuch, S. M. Blaney, S. L. Delaney, M. Hegde, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity Mol. Cancer Ther., August 1, 2009; 8(8): 2232 - 2242. [Abstract] [Full Text] [PDF]

				I. N. Fleming, M. Hogben, S. Frame, S. J. McClue, and S. R. Green Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents Clin. Cancer Res., July 1, 2008; 14(13): 4326 - 4335. [Abstract] [Full Text] [PDF]

				M. F. McCown, S. Rajyaguru, S. Le Pogam, S. Ali, W.-R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1604 - 1612. [Abstract] [Full Text] [PDF]

				C. Ji, J. Zhang, M. Dioszegi, S. Chiu, E. Rao, A. deRosier, N. Cammack, M. Brandt, and S. Sankuratri CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor Mol. Pharmacol., July 1, 2007; 72(1): 18 - 28. [Abstract] [Full Text] [PDF]

				Y. F. Brun, C. G. Dennis, W. R. Greco, R. J. Bernacki, P. J. Pera, J. J. Bushey, R. C. Youn, D. B. White, and B. H. Segal Modeling the Combination of Amphotericin B, Micafungin, and Nikkomycin Z against Aspergillus fumigatus In Vitro Using a Novel Response Surface Paradigm Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1804 - 1812. [Abstract] [Full Text] [PDF]

				R. G. Azrak, C. L. Frank, X. Ling, H. K. Slocum, F. Li, B. A. Foster, and Y. M. Rustum The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol. Cancer Ther., October 1, 2006; 5(10): 2540 - 2548. [Abstract] [Full Text] [PDF]

				T.-C. Chou Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies Pharmacol. Rev., September 1, 2006; 58(3): 621 - 681. [Abstract] [Full Text] [PDF]

				E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849. [Abstract] [Full Text] [PDF]

				P. K. Mukherjee, D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum Combination Treatment of Invasive Fungal Infections Clin. Microbiol. Rev., January 1, 2005; 18(1): 163 - 194. [Abstract] [Full Text] [PDF]

				L. Zhao, M. G. Wientjes, and J. L-S. Au Evaluation of Combination Chemotherapy: Integration of Nonlinear Regression, Curve Shift, Isobologram, and Combination Index Analyses Clin. Cancer Res., December 1, 2004; 10(23): 7994 - 8004. [Abstract] [Full Text] [PDF]

				V. H. Tam, A. N. Schilling, R. E. Lewis, D. A. Melnick, and A. N. Boucher Novel Approach to Characterization of Combined Pharmacodynamic Effects of Antimicrobial Agents Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4315 - 4321. [Abstract] [Full Text] [PDF]

				H. Minderman, K. L. O'Loughlin, L. Pendyala, and M. R. Baer VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein Clin. Cancer Res., March 1, 2004; 10(5): 1826 - 1834. [Abstract] [Full Text] [PDF]

				D. W. Selleseth, C. L. Talarico, T. Miller, M. W. Lutz, K. K. Biron, and R. J. Harvey Interactions of 1263W94 with Other Antiviral Agents in Inhibition of Human Cytomegalovirus Replication Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1468 - 1471. [Abstract] [Full Text] [PDF]

				J. Meletiadis, J. W. Mouton, J. F. G. M. Meis, and P. E. Verweij In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates Antimicrob. Agents Chemother., January 1, 2003; 47(1): 106 - 117. [Abstract] [Full Text] [PDF]

				J. Afeltra, E. Dannaoui, J. F. G. M. Meis, J. L. Rodriguez-Tudela, and P. E. Verweij In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificans Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3323 - 3326. [Abstract] [Full Text] [PDF]

				J. Wu, M.-b. Yin, G. Hapke, K. Toth, and Y. M. Rustum Induction of Biphasic DNA Double Strand Breaks and Activation of Multiple Repair Protein Complexes by DNA Topoisomerase I Drug 7-Ethyl-10-hydroxy-camptothecin Mol. Pharmacol., April 1, 2002; 61(4): 742 - 748. [Abstract] [Full Text] [PDF]

				C. S. Gavigan, S. G. Machado, J. P. Dalton, and A. Bell Analysis of Antimalarial Synergy between Bestatin and Endoprotease Inhibitors Using Statistical Response-Surface Modelling Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3175 - 3181. [Abstract] [Full Text] [PDF]

				C. J. J. G. Bol, J. P. W. Vogelaar, J.-P. Tang, and J. W. Mandema Quantification of Pharmacodynamic Interactions between Dexmedetomidine and Midazolam in the Rat J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 347 - 355. [Abstract] [Full Text]

				S. Snyder, D. Z. D'Argenio, O. Weislow, J. A. Bilello, and G. L. Drusano The Triple Combination Indinavir-Zidovudine-Lamivudine Is Highly Synergistic Antimicrob. Agents Chemother., April 1, 2000; 44(4): 1051 - 1058. [Abstract] [Full Text]

				G. M. Ferron and W. J. Jusko Species- and Gender-Related Differences in Cyclosporine/Prednisolone/Sirolimus Interactions in Whole Blood Lymphocyte Proliferation Assays J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 191 - 200. [Abstract] [Full Text]

				J.-P. Michaud A Checkerboard Method to Evaluate Interactions Between Drugs: Martinez-Irujo JJ, Villahermosa EA and Santiago E Biochemical Pharmacology, 1996; 51: 635 - 44 Human and Experimental Toxicology, October 1, 1996; 15(10): 859 - 860. [PDF]